Johnson & Johnson's RYBREVANT FASPRO receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Pharmaceutical Investing
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness Life Science Investing
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 Life Science Investing
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo Pharmaceutical Investing
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Pharmaceutical Investing
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset Pharmaceutical Investing
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union Pharmaceutical Investing
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration Life Science Investing
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET Pharmaceutical Investing
